PFKFB3 and metabolic disease: Although future studies are needed to validate a specific role for PFKFB3/iPFK2 in IECs in the control of obesity-associated insulin resistance and metabolic dysregulation, targeting PFKFB3/iPFK2 in IECs through nutritional intervention could offer novel approaches for prevention and/or treatment of inflammatory responses, which contribute to the development of obesity-associated metabolic diseases.